Sulfadiazine-induced nephrolithiasis in children

Catalano-Pons, Charlotte; Bargy, Sophie; Schlecht, Deborah; Tabone, Marie‐Dominique; Deschênes, G.; Bensman, A; Ulinski, Tim

doi:10.1007/s00467-004-1519-8

Cited by 27 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accepted treatment regimen for toxoplasmosis is pyrimethamine and sulfadiazine (33). Pyrimethamine treatment requires supplementation with folinic acid to prevent bone marrow suppression, and sulfadiazine can cause severe kidney disease in children (15) and HIV/AIDS patients (7) and can cause rashes after long-term treatment (49). These data highlight the need for the development of new anti-Toxoplasma therapies that are more effective and have fewer adverse side effects.…”

mentioning

confidence: 99%

A Novel Benzodioxole-Containing Inhibitor of Toxoplasma gondii Growth Alters the Parasite Cell Cycle

Kamau

Meehan

Lavine

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Toxoplasma gondii is an obligate intracellular parasite that can cause disease in the developing fetus and in immunocompromised humans. Infections can last for the life of the individual, and to date there are no drugs that eliminate the chronic cyst stages that are characteristic of this parasite. In an effort to identify new chemical scaffolds that could form the basis for new therapeutics, we carried out a chemoinformatic screen for compounds that had the potential to interact with members of a superfamily of parasite-secreted kinases and assayed them for growth inhibition in vitro. Of 17 candidate compounds, we identified one with potent antiparasitic activity. The compound has a 50% inhibitory concentration (IC 50 ) of ϳ2 nM, and structurefunction analyses implicate the benzodioxole moiety in its action. The compound does not appear to be cytotoxic to host cells. Using microarray analyses of both parasites and host cells treated with the compound, we found that the levels of very few host cell transcripts are altered by the compound, while a large number of parasite transcripts have a different abundance after compound treatment. Gene ontology analyses of parasite transcripts with a different abundance revealed an enrichment of cell cycle-related genes, suggesting that the compound alters progression of the parasite through the cell cycle. Assaying the nuclear content of treated parasites demonstrated that compound treatment significantly increased the percentage of parasites in the S/M phase of the cell cycle compared to controls. This compound and its analogs represent a novel scaffold with antiparasitic activity.

show abstract

mentioning

confidence: 99%

A Novel Benzodioxole-Containing Inhibitor of Toxoplasma gondii Growth Alters the Parasite Cell Cycle

Kamau

Meehan

Lavine

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…3 Recommencement of sulfadiazine therapy is not contraindicated provided there is a high urine flow rate and urine alkalinization (pH >7.15) with monitoring of renal function and urinalysis for crystals.…”

Section: Discussionmentioning

confidence: 99%

Sulfadiazine‐induced crystal nephropathy: a new ‘old’ problem

et al. 2015

View full text Add to dashboard Cite

With a greater awareness of toxoplasmosis infections, and increased prescribing of sulfadaizine, it is timely to remind colleagues of a largely forgotten clinical presentation. We present the case of crystal nephropathy secondary to sulfadiazine prescribed for retinal toxoplasmosis.A 60 year-old with left chorioretinal toxoplasmosis presented with 18 h of severe bilateral constant flank pain, nausea and acute kidney injury. He had no known renal disease. He had normal renal function prior to commencement of pyrimethamine 75 mg and sulfadiazine 1.5 g four times daily 6 days earlier.He was afebrile, blood pressure was 163/99 mmHg, and his abdominal examination revealed marked bilateral renal angle tenderness. His urine output was reduced. Initial plasma creatinine was 309 umol/L, and peaked at 530 umol/L, before rapidly improving following intervention. Urine microscopy showed many crystals, including dumbbell-shaped crystals ( Fig. 1) with a positive Lignin test. Urinalysis showed no haematuria or proteinuria, pH 6 and <10 × 10 6 white cells/L. These urinary findings confirmed a diagnosis of sulfadiazine-induced crystal nephropathy.The patient was treated with intravenous sodium bicarbonate, 0.9% saline and frusemide to achieve a urine output over 100 mL/h and urine pH above 7.15. Following 3 days of treatment, the urine was devoid of crystals, and the lignin test was now negative, indicating resolving sulfadiazineinduced crystal nephropathy. One week later, his renal function had returned to normal. DISCUSSIONSulfadiazine was well known to induce a crystal nephropathy in the two decades after it was introduced in 1936 before the availability of more water-soluble sulphonamides.1 With the relatively recent increased use of sulfadiazine to treat toxoplasmosis, sulfadiazine-induced crystal nephropathy has re-emerged as a clinical entity.Known predisposing factors to favour crystal deposition include volume depletion, hypoalbuminaemia, chronic kidney disease and inadequate dose adjustment, thereby increasing the urinary sulfadiazine concentration. A persistent acidic urinary pH (pH < 5.5) increases the likelihood of crystal deposition in the renal tubules.1 Urinary sediment examination reveals crystals typically shaped of needles, rosettes or 'shocks of wheat'. 2Treatment involves cessation of sulfadiazine, aggressive volume repletion and urine alkalization to target a urinary pH of >7.15.1 Prognosis in sulfadiazine-induced crystal nephropathy is favourable, with renal recovery over a mean of 8.3 days.3 Recommencement of sulfadiazine therapy is not contraindicated provided there is a high urine flow rate and urine alkalinization (pH >7.15) with monitoring of renal function and urinalysis for crystals.

show abstract

“…Over-dosage of sulfonamides can cause allergic reactions, antibiotic resistance, and carcinogenic effects (Hasebe and Osteryoung, 1975). Because of poor water solubility, sulfonamides can also lead to urinary tract lithiasis such as renal calculus and vesical calculus (Catalano-Pons et al, 2004). Therefore, quick systematic monitoring of sulfonamides in body fluids is an important analytical task.…”

Section: Introductionmentioning

confidence: 99%

“…Sulfonamides are broad-spectrum and low-cost synthetic antibiotics used in treatment of diseases such as urinary tract infections, pneumocystis pneumonia, chronic bronchitis, meningococcal meningitis, and toxoplasmosis (Catalano-Pons et al, 2004;Joseph and Kumar, 2010). Over-dosage of sulfonamides can cause allergic reactions, antibiotic resistance, and carcinogenic effects (Hasebe and Osteryoung, 1975).…”

Section: Introductionmentioning

confidence: 99%

Electrocatalytic response of poly(cobalt tetraaminophthalocyanine)/multi-walled carbon nanotubes-Nafion modified electrode toward sulfadiazine in urine

Hong

Zhu

Zhang

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:A highly sensitive amperometric sulfadiazine sensor fabricated by electrochemical deposition of poly(cobalt tetraaminophthalocyanine) (poly(Co II TAPc)) on the surface of a multi-walled carbon nanotubes-Nafion (MWCNTs-Nafion) modified electrode is described. This electrode showed a very attractive performance by combining the advantages of Co II TAPc, MWCNTs, and Nafion. Compared with the bare glassy carbon electrode (GCE) and the MWCNTs-Nafion modified electrode, the electrocatalytic activity of poly(Co II TAPc)-coated MWCNTs-Nafion GCE generated greatly improved electrochemical detections toward sulfadiazine including low oxidation potential, high current responses, and good anti-fouling performance. The oxidation peak currents of sulfadiazine obtained on the new modified electrode increased linearly while increasing the concentration of sulfadiazine from 0.5 to 43.5 μmol/L with the detection limit of 0.17 μmol/L.

show abstract

Sulfadiazine-induced nephrolithiasis in children

Cited by 27 publications

References 20 publications

A Novel Benzodioxole-Containing Inhibitor of Toxoplasma gondii Growth Alters the Parasite Cell Cycle

A Novel Benzodioxole-Containing Inhibitor of Toxoplasma gondii Growth Alters the Parasite Cell Cycle

Sulfadiazine‐induced crystal nephropathy: a new ‘old’ problem

Electrocatalytic response of poly(cobalt tetraaminophthalocyanine)/multi-walled carbon nanotubes-Nafion modified electrode toward sulfadiazine in urine

Contact Info

Product

Resources

About